277 related articles for article (PubMed ID: 35250880)
1. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease.
Yang C; He Q; Chen Z; Qin JJ; Lei F; Liu YM; Liu W; Chen MM; Sun T; Zhu Q; Wu Y; Zhuo M; Cai J; Mao W; Li H
Front Endocrinol (Lausanne); 2022; 13():821689. PubMed ID: 35250880
[TBL] [Abstract][Full Text] [Related]
2. Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study.
Sung KC; Yoo TK; Lee MY; Byrne CD; Zheng MH; Targher G
Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):482-491. PubMed ID: 36727522
[TBL] [Abstract][Full Text] [Related]
3. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
4. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
[TBL] [Abstract][Full Text] [Related]
5. Association of MAFLD With Diabetes, Chronic Kidney Disease, and Cardiovascular Disease: A 4.6-Year Cohort Study in China.
Liang Y; Chen H; Liu Y; Hou X; Wei L; Bao Y; Yang C; Zong G; Wu J; Jia W
J Clin Endocrinol Metab; 2022 Jan; 107(1):88-97. PubMed ID: 34508601
[TBL] [Abstract][Full Text] [Related]
6. The Role of Metabolic Dysfunction-Associated Fatty Liver Disease in Developing Chronic Kidney Disease: Longitudinal Cohort Study.
Wei S; Song J; Xie Y; Huang J; Yang J
JMIR Public Health Surveill; 2023 May; 9():e45050. PubMed ID: 37140958
[TBL] [Abstract][Full Text] [Related]
7. Hyperuricemia precedes non-alcoholic fatty liver disease with abdominal obesity moderating this unidirectional relationship: Three longitudinal analyses.
Ma Z; Zhang J; Kang X; Xu C; Sun C; Tao L; Zheng D; Han Y; Li Q; Guo X; Yang X
Atherosclerosis; 2020 Oct; 311():44-51. PubMed ID: 32937242
[TBL] [Abstract][Full Text] [Related]
8. An Observational and Cross-Sectional Study of the Prevalence of Breast Lesions and Metabolic Dysfunction-Associated Fatty Liver Disease and their Relationship in China.
Li S; Xu Z; Li H; Tang J; Liang XY; Tian S; Wu J; Li X; Liu ZL; Xiao J; Chen YL; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
J Gastrointestin Liver Dis; 2022 Mar; 31(1):31-39. PubMed ID: 35306559
[TBL] [Abstract][Full Text] [Related]
9. Metabolic dysfunction-associated fatty liver disease increased the risk of subclinical carotid atherosclerosis in China.
Lei F; Wang XM; Wang C; Huang X; Liu YM; Qin JJ; Zhang P; Ji YX; She ZG; Cai J; Li HP; Zhang XJ; Li H
Front Endocrinol (Lausanne); 2023; 14():1109673. PubMed ID: 37082131
[TBL] [Abstract][Full Text] [Related]
10. Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study.
Jung CY; Koh HB; Park KH; Joo YS; Kim HW; Ahn SH; Park JT; Kim SU
Diabetes Metab; 2022 Jul; 48(4):101344. PubMed ID: 35346856
[TBL] [Abstract][Full Text] [Related]
11. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
[TBL] [Abstract][Full Text] [Related]
12. Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease.
Liu J; Lv H; Wang J; Zhu Q; Chen G; Jiang Y; Zhao K; Shao L; Shi J; Pan X
Ann Hepatol; 2023; 28(2):100892. PubMed ID: 36577468
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG
Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138
[TBL] [Abstract][Full Text] [Related]
14. MAFLD and risk of CKD.
Sun DQ; Jin Y; Wang TY; Zheng KI; Rios RS; Zhang HY; Targher G; Byrne CD; Yuan WJ; Zheng MH
Metabolism; 2021 Feb; 115():154433. PubMed ID: 33212070
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study.
Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ
BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822
[TBL] [Abstract][Full Text] [Related]
16. The association between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: A systematic review and meta-analysis.
Agustanti N; Soetedjo NNM; Damara FA; Iryaningrum MR; Permana H; Bestari MB; Supriyadi R
Diabetes Metab Syndr; 2023 May; 17(5):102780. PubMed ID: 37201293
[TBL] [Abstract][Full Text] [Related]
17. Hyperuricemia as an independent risk factor for metabolic dysfunction-associated fatty liver disease in nonobese patients without type 2 diabetes mellitus.
Liu J; Wang C; Wang YT; Liu JX; Zhou TH; Yao SK; Chen G
Am J Physiol Endocrinol Metab; 2023 Jul; 325(1):E62-E71. PubMed ID: 37285598
[TBL] [Abstract][Full Text] [Related]
18. Associations of metal mixtures with metabolic-associated fatty liver disease and non-alcoholic fatty liver disease: NHANES 2003-2018.
Xie Z; Aimuzi R; Si M; Qu Y; Jiang Y
Front Public Health; 2023; 11():1133194. PubMed ID: 36950101
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
Moon JH; Kim W; Koo BK; Cho NH;
Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study.
Kim KS; Hong S; Ahn HY; Park CY
Diabetes Metab J; 2023 Mar; 47(2):220-231. PubMed ID: 36631994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
